Angiomyolipomas News and Research

RSS
Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Everolimus treatment option for tuberous sclerosis patients

Everolimus treatment option for tuberous sclerosis patients

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

Novartis receives FDA approval for Afinitor Disperz to treat subependymal giant cell astrocytoma

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

TSC proteins regulate Notch activity

TSC proteins regulate Notch activity

Lymphangioleiomyomatosis -  potential clues into the treatment and diagnosis

Lymphangioleiomyomatosis - potential clues into the treatment and diagnosis